Jazz Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 1/6

Jazz Pharmaceuticals şirketinin kazançları yıllık ortalama -26.6% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 0.2% oranında azalan oldu. Gelirler yıllık ortalama 15.1% oranında artan oldu. Jazz Pharmaceuticals şirketinin öz sermaye getirisi 10.5% olup, net marjı 10.1% dir.

Anahtar bilgiler

-26.6%

Kazanç büyüme oranı

-28.9%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	6.0%
Gelir büyüme oranı	15.1%
Özkaynak getirisi	10.5%
Net Marj	10.1%
Sonraki Kazanç Güncellemesi	06 Nov 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Oct 22

Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook

Oct 16

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 25

Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst

Sep 19

Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Jul 18

Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Apr 02

Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Feb 18

Updated View On Jazz Pharmaceuticals' 2025 Goals

Jan 29

Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Dec 26

Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Oct 31

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Jul 12

We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Apr 12

Gelir ve Gider Dağılımı

Jazz Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:JAZZ Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	3,910	395	1,359	869
31 Mar 24	3,843	331	1,361	857
31 Dec 23	3,834	415	1,307	824
30 Sep 23	3,794	80	1,290	782
30 Jun 23	3,763	-87	1,378	685
31 Mar 23	3,738	-156	1,397	615
31 Dec 22	3,659	-224	1,399	555
30 Sep 22	3,584	-19	1,276	532
30 Jun 22	3,481	-52	1,222	536
31 Mar 22	3,300	-450	1,291	530
31 Dec 21	3,094	-330	1,399	476
30 Sep 21	2,863	-161	1,326	416
30 Jun 21	2,626	40	1,170	354
31 Mar 21	2,436	518	926	306
31 Dec 20	2,364	239	880	310
30 Sep 20	2,280	179	846	316
30 Jun 20	2,217	133	818	317
31 Mar 20	2,188	280	808	295
31 Dec 19	2,162	523	762	275
30 Sep 19	2,056	609	626	259
30 Jun 19	1,988	656	662	230
31 Mar 19	1,954	486	586	224
31 Dec 18	1,891	447	625	227
30 Sep 18	1,851	520	667	234
30 Jun 18	1,793	434	578	230
31 Mar 18	1,687	447	610	214
31 Dec 17	1,619	488	544	198
30 Sep 17	1,579	372	518	175
30 Jun 17	1,541	399	505	175
31 Mar 17	1,528	408	496	174
31 Dec 16	1,488	397	480	160
30 Sep 16	1,432	363	470	148
30 Jun 16	1,399	361	462	151
31 Mar 16	1,352	335	447	139
31 Dec 15	1,325	330	433	133
30 Sep 15	1,312	328	422	130
30 Jun 15	1,278	266	411	102
31 Mar 15	1,235	222	399	94
31 Dec 14	1,173	58	404	85
30 Sep 14	1,081	32	350	74
30 Jun 14	1,006	82	327	64
31 Mar 14	923	80	305	53
31 Dec 13	872	216	281	42

Kaliteli Kazançlar: JAZZ büyük bir tek seferlik zarar ile $215.1M, 30th June, 2024 tarihine ait son 12 aylık mali sonuçları etkiliyor.

Büyüyen Kar Marjı: JAZZ geçmişte karlı hale geldi.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: JAZZ şirketinin kazançları son 5 yılda yılda 26.6% oranında azaldı.

Büyüme Hızlandırma: JAZZ son bir yılda karlı hale geldi, bu da kazanç büyüme oranının 5 yıllık ortalamayla karşılaştırılmasını zorlaştırıyor.

Kazançlar vs. Sektör: JAZZ son bir yılda karlı hale geldi ve bu durum, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 12.7% ) karşılaştırılmasını zorlaştırıyor.

Özkaynak Getirisi

Yüksek ROE: JAZZ 'nin Özsermaye Getirisi ( 10.5% ) düşük olarak değerlendiriliyor.

Jazz Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 1/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Jazz Pharmaceuticals plc to Report Q3, 2024 Results on Nov 06, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Jazz Pharmaceuticals plc to Report Q2, 2024 Results on Jul 25, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Jazz Pharmaceuticals plc to Report Q1, 2024 Results on May 01, 2024

Full year 2023 earnings: EPS misses analyst expectations

Recent updates

Jazz Pharmaceuticals plc Presents New Data at Psych Congress 2024 Confirming Xywav®? (Calcium, Potent, and Sodium Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia

Jazz Pharmaceuticals plc to Report Q3, 2024 Results on Nov 06, 2024

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook

Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (Lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough

Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from FTSE All-World Index (USD)

Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst

Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024

gJazz Pharmaceuticals plc to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex/Epidyolex®? (Cannabidiol) At the European Epilepsy Congress 2024

Jazz Pharmaceuticals plc Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies

Consensus EPS estimates increase by 25%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) announces an Equity Buyback for $500 million worth of its shares.

Jazz Pharmaceuticals plc Elect Laura Hamill to the Board of Directors

Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely

Jazz Pharmaceuticals plc to Report Q2, 2024 Results on Jul 25, 2024

Jazz Pharmaceuticals plc Promotes Samantha Pearce to Chief Commercial Officer

Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell 2500 Growth Index

Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden

Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues

Jazz Pharmaceuticals plc Provides Update on Phase 2b Trial of Investigational Suvecaltamide in Essential Tremor

Jazz Pharmaceuticals plc, Annual General Meeting, Jul 25, 2024

Jazz Pharmaceuticals plc Announces Catherine Sohn, Pharm.D. Will Not Stand for Re-Election to the Board

New minor risk - Insider selling

Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024

Jazz Pharmaceuticals plc Announces the U.S. Food and Drug Administration Accepted and Granted Priority Review of the Biologics License Application (BLA) for Zanidatamab

Executive VP & Chief Legal Officer recently sold US$548k worth of stock

Executive VP & Chief Legal Officer notifies of intention to sell stock

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Jazz Pharmaceuticals plc Affirms Earnings Guidance for the Full Year 2024

Jazz Pharmaceuticals plc to Report Q1, 2024 Results on May 01, 2024

Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off

Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer

Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Executive VP & CFO recently bought US$1.4m worth of stock

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 41%

New minor risk - Earnings quality

Full year 2023 earnings: EPS misses analyst expectations

Jazz Pharmaceuticals plc Provides Earnings Guidance for the Full Year 2024

Jazz Pharmaceuticals Announces Board Changes

Jazz Pharmaceuticals plc Appoints Philip Johnson as Executive Vice President, Effective March 1, 2024

Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Jazz Pharmaceuticals plc to Report Q4, 2023 Results on Feb 28, 2024

Updated View On Jazz Pharmaceuticals' 2025 Goals

Insufficient new directors

Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Kim Sablich to Departure as Executive Vice President and General Manager, US of Jazz Pharmaceuticals plc on December 31, 2023

Jazz Pharmaceuticals plc to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Annual Meeting

Third quarter 2023 earnings: EPS misses analyst expectations

Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Jazz Pharmaceuticals plc to Report Q3, 2023 Results on Nov 08, 2023

Jazz Pharmaceuticals plc Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xyw

Jazz Pharmaceuticals plc to Present Data from Trials of Bispecific Antibody Zanidatamab and Zepzelca

Jazz Pharmaceuticals plc Receives European Commission Approval for Enrylaze® for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Jazz Pharmaceuticals plc Announces Chief Financial Officer Changes, October 1, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Jazz Pharmaceuticals plc Revises Earnings Guidance for the Year 2023

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation

Jazz Pharmaceuticals plc to Report Q2, 2023 Results on Aug 09, 2023

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Jazz Pharmaceuticals plc, Annual General Meeting, Aug 03, 2023

Executive VP & Chief Legal Officer notifies of intention to sell stock

Jazz Pharmaceuticals plc and Zymeworks Inc. Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

Jazz Pharmaceuticals plc Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023

Insider recently sold US$790k worth of stock